These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7679331)

  • 1. Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.
    Smith DC; Jodrell DI; Egorin MJ; Ambinder RM; Zuhowski EG; Kreis W; Ellis PG; Trump DL
    Cancer Chemother Pharmacol; 1993; 31(5):363-8. PubMed ID: 7679331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro cytotoxic effect of melphalan and pilot phase II study in hormone-refractory prostate cancer.
    Mougenot P; Bressolle F; Culine S; Solassol I; Poujol S; Pinguet F
    Anticancer Res; 2006; 26(3B):2197-203. PubMed ID: 16821586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 study.
    Shamash J; Jacob J; Agrawal S; Powles T; Mutsvangwa K; Wilson P; Stebbing J
    Clin Cancer Res; 2012 Apr; 18(8):2352-9. PubMed ID: 22392912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
    Mougenot P; Pinguet F; Fabbro M; Culine S; Poujol S; Astre C; Bressolle F
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):503-12. PubMed ID: 15007638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
    Picus J; Schultz M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.
    Hudes GR; Greenberg R; Krigel RL; Fox S; Scher R; Litwin S; Watts P; Speicher L; Tew K; Comis R
    J Clin Oncol; 1992 Nov; 10(11):1754-61. PubMed ID: 1383436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.
    Samelis GF; Skarlos D; Bafaloukos D; Kosmidis P; Anagnostopoulos A; Aravantinos G; Dimopoulos MA;
    Urology; 2003 Jun; 61(6):1211-5. PubMed ID: 12809899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
    Salzberg M; Rochlitz C; Morant R; Thalmann G; Pedrazzini A; Roggero E; Schönenberger A; Knuth A; Borner M
    Onkologie; 2007 Jul; 30(7):355-60. PubMed ID: 17596743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
    Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin in advanced hormone refractory prostatic cancer patients.
    Canobbio L; Guarneri D; Miglietta L; Decensi A; Oneto F; Boccardo F
    Eur J Cancer; 1993; 29A(15):2094-6. PubMed ID: 7507687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does failure of single hormone therapy delineate hormone refractoriness for prostate cancer?
    Kotwal S; Whelan P
    Scand J Urol Nephrol; 2008; 42(2):116-20. PubMed ID: 17907049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
    Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
    Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
    Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
    Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
    J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer.
    Small EJ; Fippin LJ; Whisenant SP
    Cancer Invest; 1998; 16(7):456-61. PubMed ID: 9774952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
    Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
    J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group.
    Moore MM; Stockler M; Lim R; Mok TS; Millward M; Boyer MJ
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):845-50. PubMed ID: 20082080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland.
    Schmid HP; Maibach R; Bernhard J; Hering F; Hanselmann S; Gusset H; Morant R; Pestalozzi D; Castiglione M
    Cancer; 1997 May; 79(9):1703-9. PubMed ID: 9128985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.